The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy
Open accessAbstract
Background: Efficient and specific induction of cell death in liver cancer is urgently needed.In this study, we aimed to design an exosome-based platform to deliver ferroptosis inducer (Erastin, Er) and photosensitizer (Rose Bengal, RB) into tumor tissues with high specificity.Methods: Exosome donor cells (HEK293T) were transfected with control or CD47-overexpressing plasmid.Exosomes were isolated and loaded with Er and RB via sonication method.Hepa1-6 cell xenograft C57BL/6 model was injected with control and engineered exosomes via tail vein.In vivo distribution of the injected exosomes was analyzed via tracking the fluorescence labeled exosomes.Photodynamic therapy was conducted by 532 nm laser irradiation.The therapeutic effects on hepatocellular carcinoma and toxic side-effects were systemically analyzed.Results: CD47 was efficiently loaded on the exosomes from the donor cells when CD47 was forced expressed by transfection.CD47 surface functionalization (Exos CD47 ) made the exosomes effectively escape the phagocytosis of mononuclear phagocyte system (MPS), and thus increased the distribution in tumor tissues.Erastin and RB could be effectively encapsulated into exosomes after sonication, and the drug-loaded exosomes (Er/RB@Exos CD47 ) strongly induced ferroptosis both in vitro and in vivo in tumor cells after irradiation of 532 nm laser.Moreover, compared with the control exosomes (Er/RB@Exos Ctrl ), Er/RB@Exos CD47 displayed much lower toxicity in liver.Conclusion: The engineered exosomes composed of CD47, Erastin, and Rose Bengal, induce obvious ferroptosis in hepatocellular carcinoma (HCC) with minimized toxicity in liver and kidney.The proposed exosomes would provide a promising strategy to treat types of malignant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145 · cited 1×
“In PDT, molecular oxygen can be converted into reactive oxygen species (ROS) by photosensitizers (PSs) in their respective excited states [46].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice
Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3064 · Cited by 3,732
Pegtel, D. M., & Gould, S. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111902 · Cited by 2,682
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639
Timmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573 · cited 1×
“Erastin, as a classic ferroptosis inducer, has been explored in the treatment of tumors which can directly inhibit the activity of the system xc- [10, 17].”
BackgroundPlatelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy
Jiang, Q., Wang, K., Zhang, X., Ouyang, B., Liu, H., Pang, Z., & Yang, W. (2020) · Small · doi:10.1002/smll.202001704 · Cited by 426
Li, Z., Zhou, X., Wei, M., Gao, X., Zhao, L., Shi, R., Sun, W., Duan, Y., Yang, G., & Yuan, L. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b02689 · Cited by 318
Self-citationHu, C., Nydes, M., Shanley, K. L., Morales Pantoja, I. E., Howard, T. A., & Bizzozero, O. A. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14604 · Cited by 200
Cited by
Tong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01392-3 · Cited by 883
Engineered exosomes from different sources for cancer-targeted therapy
Zhang, M., Hu, S., Liu, L., Dang, P., Liu, Y., Sun, Z., Qiao, B., & Wang, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01382-y · Cited by 468
Self-citationLiquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring
Li, W., Liu, J.-B., Hou, L.-K., Yu, F., Zhang, J., Wu, W., Tang, X.-M., Sun, F., Lu, H.-M., Deng, J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01505-z · Cited by 457
Current Strategies for Exosome Cargo Loading and Targeting Delivery
Zeng, H., Guo, S., Ren, X., Wu, Z., Liu, S., & Yao, X. (2023) · Cells · doi:10.3390/cells12101416 · Cited by 424
Extracellular vesicles: a rising star for therapeutics and drug delivery
Du, S., Guan, Y., Xie, A., Yan, Z., Gao, S., Li, W., Rao, L., Chen, X., & Chen, T. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01973-5 · Cited by 314
Metadata
- Authors
- Du, J., Wan, Z., Wang, C., Lu, F., Wei, M., Wang, D., & Hao, Q.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2021
- Volume
- 11
- Issue
- 17
- Pages
- 8185-8196
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3184370336
- Cited by
- 233
- References
- 9
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.